RU2018119732A - Полипептиды против il-23 - Google Patents
Полипептиды против il-23 Download PDFInfo
- Publication number
- RU2018119732A RU2018119732A RU2018119732A RU2018119732A RU2018119732A RU 2018119732 A RU2018119732 A RU 2018119732A RU 2018119732 A RU2018119732 A RU 2018119732A RU 2018119732 A RU2018119732 A RU 2018119732A RU 2018119732 A RU2018119732 A RU 2018119732A
- Authority
- RU
- Russia
- Prior art keywords
- polypeptide
- seq
- amino acid
- acid sequence
- polypeptide according
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (6)
1. Полипептид, имеющий аминокислотную последовательность, выбранную из аминокислотных последовательностей SEQ ID NO: 2 и SEQ ID NO: 3.
2. Полипептид, имеющий аминокислотную последовательность SEQ ID NO: 2.
3. Полипептид, имеющий аминокислотную последовательность SEQ ID NO: 3.
4. Композиция, содержащая полипептид по п. 1.
5. Полипептид по п. 1 для предотвращения или лечения заболевания, связанного с IL-23 и/или с сигнальными путями, опосредованными IL-23.
6. Полипептид по п. 1 для предотвращения или лечения воспаления и воспалительных расстройств, таких как заболевания кишечника (колит, болезнь Крона, IBD), инфекционные заболевания, псориаз, рак, аутоиммунные заболевания (такие как множественный склероз), саркоидоз, отторжение трансплантата, кистозный фиброз, астма, хроническая обструктивная болезнь легких, ревматоидный артрит, вирусная инфекция, вариабельный неклассифицируемый иммунодефицит.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562248468P | 2015-10-30 | 2015-10-30 | |
| US62/248,468 | 2015-10-30 | ||
| PCT/EP2016/076076 WO2017072299A1 (en) | 2015-10-30 | 2016-10-28 | Polypeptides against il-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018119732A true RU2018119732A (ru) | 2019-12-03 |
| RU2018119732A3 RU2018119732A3 (ru) | 2020-03-24 |
Family
ID=57218890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018119732A RU2018119732A (ru) | 2015-10-30 | 2016-10-28 | Полипептиды против il-23 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10968271B2 (ru) |
| EP (1) | EP3368569B1 (ru) |
| JP (1) | JP6936797B2 (ru) |
| KR (1) | KR20180072819A (ru) |
| CN (1) | CN108350069B (ru) |
| AU (1) | AU2016347610A1 (ru) |
| BR (1) | BR112018008754A2 (ru) |
| CA (1) | CA3003539A1 (ru) |
| IL (1) | IL258897A (ru) |
| MX (1) | MX2018005411A (ru) |
| RU (1) | RU2018119732A (ru) |
| SG (1) | SG11201803416VA (ru) |
| WO (1) | WO2017072299A1 (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL318433A (en) * | 2014-05-16 | 2025-03-01 | Ablynx Nv | Improved immunoglobulin variable complexes |
| RS63085B1 (sr) | 2014-05-16 | 2022-04-29 | Ablynx Nv | Varijabilni domeni imunoglobulina |
| RU2018119732A (ru) | 2015-10-30 | 2019-12-03 | Аблинкс Нв | Полипептиды против il-23 |
| WO2020176478A1 (en) | 2019-02-25 | 2020-09-03 | The University Of Chicago | Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents |
| CN114920839B (zh) * | 2022-06-17 | 2023-03-10 | 天津大学 | 特异性结合il-23的纳米抗体及其用途 |
| WO2024133935A1 (en) | 2022-12-23 | 2024-06-27 | Ablynx Nv | Protein-based conjugation carriers |
| AU2024221136A1 (en) | 2023-02-17 | 2025-10-02 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| MX2010005783A (es) | 2007-11-27 | 2010-08-10 | Ablynx Nv | Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas. |
| EP3828201A1 (en) | 2009-04-30 | 2021-06-02 | Ablynx N.V. | Method for the production of domain antibodies |
| WO2010142534A1 (en) * | 2009-05-27 | 2010-12-16 | Ablynx Nv | Biparatopic protein constructs directed against il-23 |
| KR101721187B1 (ko) | 2009-12-23 | 2017-03-29 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 면역원성의 감소 방법 |
| CN102971341A (zh) * | 2010-04-30 | 2013-03-13 | 埃博灵克斯股份有限公司 | 针对异二聚体细胞因子IL-23的p19亚基的纳米抗体的氨基酸序列 |
| AU2011282476B2 (en) * | 2010-07-20 | 2015-08-20 | Cephalon Australia Pty Ltd | Anti-IL-23 heterodimer specific antibodies |
| DE102011077786A1 (de) | 2011-06-20 | 2012-12-20 | Continental Teves Ag & Co. Ohg | Aktuatorsystem und Betriebsverfahren für ein Aktuatorsystem |
| PH12022550311A1 (en) | 2011-06-23 | 2023-01-23 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| KR102143506B1 (ko) | 2011-08-17 | 2020-08-12 | 글락소 그룹 리미티드 | 변형된 단백질 및 펩티드 |
| WO2014111550A1 (en) * | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| RU2018119732A (ru) | 2015-10-30 | 2019-12-03 | Аблинкс Нв | Полипептиды против il-23 |
| JP7046804B2 (ja) | 2015-11-18 | 2022-04-04 | アブリンクス エン．ヴェー． | 改良された血清アルブミン結合剤 |
-
2016
- 2016-10-28 RU RU2018119732A patent/RU2018119732A/ru not_active Application Discontinuation
- 2016-10-28 SG SG11201803416VA patent/SG11201803416VA/en unknown
- 2016-10-28 KR KR1020187015320A patent/KR20180072819A/ko not_active Withdrawn
- 2016-10-28 CA CA3003539A patent/CA3003539A1/en not_active Abandoned
- 2016-10-28 EP EP16788684.5A patent/EP3368569B1/en active Active
- 2016-10-28 BR BR112018008754A patent/BR112018008754A2/pt not_active Application Discontinuation
- 2016-10-28 AU AU2016347610A patent/AU2016347610A1/en not_active Abandoned
- 2016-10-28 MX MX2018005411A patent/MX2018005411A/es unknown
- 2016-10-28 WO PCT/EP2016/076076 patent/WO2017072299A1/en not_active Ceased
- 2016-10-28 CN CN201680063284.6A patent/CN108350069B/zh active Active
- 2016-10-28 US US15/769,864 patent/US10968271B2/en active Active
- 2016-10-28 JP JP2018521975A patent/JP6936797B2/ja active Active
-
2018
- 2018-04-24 IL IL258897A patent/IL258897A/en unknown
-
2021
- 2021-03-01 US US17/188,158 patent/US11753465B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018008754A2 (pt) | 2018-10-30 |
| US20180312583A1 (en) | 2018-11-01 |
| CN108350069A (zh) | 2018-07-31 |
| EP3368569A1 (en) | 2018-09-05 |
| AU2016347610A1 (en) | 2018-05-10 |
| US11753465B2 (en) | 2023-09-12 |
| SG11201803416VA (en) | 2018-05-30 |
| US10968271B2 (en) | 2021-04-06 |
| CN108350069B (zh) | 2021-11-12 |
| IL258897A (en) | 2018-06-28 |
| KR20180072819A (ko) | 2018-06-29 |
| US20210188967A1 (en) | 2021-06-24 |
| JP6936797B2 (ja) | 2021-09-22 |
| JP2018538251A (ja) | 2018-12-27 |
| RU2018119732A3 (ru) | 2020-03-24 |
| WO2017072299A1 (en) | 2017-05-04 |
| MX2018005411A (es) | 2018-08-15 |
| CA3003539A1 (en) | 2017-05-04 |
| EP3368569B1 (en) | 2021-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018119732A (ru) | Полипептиды против il-23 | |
| JP2016521688A5 (ru) | ||
| Tassopoulos et al. | Α two-phase adaptive variable neighborhood approach for nurse rostering | |
| ZA202004980B (en) | A modified raav capsid protein for gene therapy | |
| JP2016063812A5 (ru) | ||
| WO2017106346A3 (en) | Human immunodeficiency virus neutralizing antibodies | |
| EA201992882A1 (ru) | САМОРЕГУЛИРУЕМЫЕ ВЕКТОРЫ НА ОСНОВЕ AAV ДЛЯ БЕЗОПАСНОЙ ЭКСПРЕССИИ MeCP2 ПРИ СИНДРОМЕ PETTA | |
| JP2016515524A5 (ru) | ||
| MX2017008604A (es) | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 especifica de ubiquitina. | |
| WO2015155686A3 (en) | Methods and compositions for rna-directed repression of transcription using crispr-associated genes | |
| EA201890640A1 (ru) | Рекомбинантные векторы, содержащие пептид 2а | |
| DK3807413T3 (da) | Adenoassocieret virusvektorfremføring af muskelspecifik mikrodystrofin til behandling af muskeldystrofi | |
| WO2017189964A3 (en) | Compositions for the treatment of disease | |
| WO2015140051A8 (en) | Heteroaryl syk inhibitors | |
| PH12017550134A1 (en) | Il-37 variants | |
| WO2016127179A3 (en) | Immunomodulatory agents | |
| EA201890072A1 (ru) | Новые соединения в качестве модуляторов ror-гамма | |
| EP3443093A4 (en) | TREATMENT OF IDIOPATHIC LUNG FIBROSIS WITH RNA COMPLEXES TARGETED AGAINST THE TISSUE GROWTH FACTOR | |
| EA202090401A1 (ru) | Анти-tim-3 антитела и их применение | |
| IL286475A (en) | Methods for the manufacture of recombinant viral vectors | |
| HK1244201A1 (zh) | 芋螺毒素(conotoxin)肽的修饰和用途 | |
| MX392849B (es) | Composiciones novedosas y métodos terapéuticos. | |
| WO2015187521A3 (en) | Anti-blys antibodies | |
| EP3451859A4 (en) | FUNCTIONALLY REINSTALLED DESALINATED FOOD COMPOSITIONS FROM HALOPHYTES AND PRODUCTION METHODS THEREFOR | |
| WO2016009451A3 (en) | A novel process for purification of rhu-gcsf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20211208 |